Aspargo Labs’ business model is repeatable and applies our proprietary technology to the world’s most meaningful compounds and brands.
Current and near-term projects have strong IP protection through 2036, including Oral Suspension for Sildenafil (VIAGRA®) through 2036.
Multiple patents granted for future digitally connected drug delivery device.
Aspargo Labs has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) as part of the process to become a publicly traded company. This filing includes details about the company’s business, financials, and the proposed listing of our shares on the New York Stock Exchange.
You can view the filed S-1 registration statement on the SEC’s database HERE.
Stay informed with our latest updates:
Phase 1 study published in International Journal of Science and Research shows absorption of ASP-001 within 5 minutes, which is markedly faster than Viagra tablets
Dosing complete for 53 subjects in Sildenafil Oral Suspension Bioavailability Study Initiated dosing in 38 subjects in Sildenafil Oral Suspension Food-Effect Study Top-line data from
Study will compare bioavailability of Sildenafil Oral Suspension and Viagra® tablets under fasted conditions Companion study will evaluate the effects of food on the bioavailability
Company plans to initiate clinical trials in September 2023 to compare Sildenafil Oral Spray to Viagra® tablets, and effect of dose administration under fasted versus fed
Planned bioequivalence study in healthy adult male subjects will compare the rate and extent of absorption of ASP-001 (Sildenafil Oral Spray) versus Viagra® tablets Companion food-effect
The aggregate German, Irish and Dutch market for erectile dysfunction (ED) market exceeds $175 million Aspargo plans to launch Sildenafil Spray in Germany, Ireland, and